creat chapter natur
end market remain solid manag maintain upgrad
outlook rest year
pthn ahead manag intern schedul strength
 contribut part guidanc rais
analyt technolog core driven strength across
margin expect declin upcom qs due busi mix
thesi updat video game would rampag
continu decim qs st estim find hard
believ key debat coupl year ago tmo core
could break admit put bit
ordinari tmo end market continu robust high
growth acquisit perform expect would surpris
debat chang tmo abil grow core throw
gauntlet find stock reaction print baffl
larg cap healthcar stock provid clear visibl
consist solid mid-teen ep growth addit see upsid
number given current favor macro environ look
directli china continu strong perform pthn
fei thu encourag investor buy tmo weak today hand
fist stock remain must-own core hold larg cap land
reiter outperform rate rais pt
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
 fx tw vs prior guidanc core fx tw
rais ep vs prior
 maintain tax cash tax expect slightli lower
 ep cadenc remaind fy
 face strong comp
 ep phase
growth came bp better guidanc
north america lsd continu see similar trend region
china high-teen broad strength across end market
 pharma biotech market quit robust
biopharma notabl strength bioproduct
 hsd notabl strength bioscienc
dx healthcar hsd us healthcar channel strong flu partial off-set weaker allergi test
indust/appli msd recoveri full effect improv across region
tax bp due us tax reform pthn discret tax line item
margin mainli due mix pthn dilut partial off-set continu product improv ppi
expect mm share repo mm dividend
million except per share data fy end decemb organ organ product organ scienc organ organ gp less total product scienc op less ep share inc net inc price-to-earnings prem disc april
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin april et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
